Single-Use Biopsy and Puncture Needles — South Korea Registration Guide

Key takeaway — Biopsy and puncture needles are simple in design, so the performance review is short. The questions reviewers actually ask are these: "Is the device sterile, made of safe materials, and does that hold for the entire shelf life?" The centre of gravity of the submission sits on three axes — sterilization validation, biological safety, and packaging validation — and that is also where almost every deficiency letter comes from.

Same needle, different class — classification is the first step

Biopsy needles (tissue sampling) and puncture needles (puncture and aspiration) are distinct in clinical use, but from a regulatory standpoint the first question is a single one: single-use and sterile, or reusable? The answer determines both the class and the pathway.

Type	Use	Typical class	Supply form
Single-use puncture needle	Puncture of tissue/body fluid, injection and aspiration	Class II	Sterile
Biopsy needle / kit	Collection and aspiration of tissue for examination	Class II	Sterile
Reusable puncture needle	Repeated use after re-sterilization	Class I	May be non-sterile

Single-use sterile products normally fall in the Class II range and follow the certification pathway with technical documentation review (roughly 3–4 months). The overall framework is the same as in the Class II certification guide. This is a well-standardised product category — MFDS maintains a dedicated "Guideline on the Approval and Preparation of Technical Documentation for Single-Use Puncture Needles" — but the assigned product name can differ depending on the design (core type, aspiration type, and so on) and the claimed intended use, so fixing the classification early in development is the safe move. If you first take a look at how notification, certification and approval diverge in the procedure overview, the rest reads more easily.

The five axes the review focuses on

1. Raw material information — data that traces the supply chain upstream. For every component — the needle (stainless steel), the hub (plastic), the protective cap — you must specify the material name, the grade, and whether it contacts the body. The trap is that the manufacturer often does not know. If the manufacturer buys raw material from outside, you need the upstream supplier's material certificates (mill sheets and similar), and obtaining that documentation is a classic bottleneck in import projects. A single line saying "SUS304" is not enough: the grade used on the contacting portion, the surface treatment, and any coating (silicone coating, for example) must all be specified before you can move on to the next step, the biological safety evaluation.

2. Biological safety — the contact site and duration determine the test battery. Biopsy and puncture needles contact blood and tissue directly, so ISO 10993-series evaluation is the core. Cytotoxicity, sensitization and irritation are the usual baseline, with haemocompatibility and related endpoints added depending on the blood-contact profile. It is the contact duration category that decides which branch of testing applies. The internationally used categories are limited contact (up to 24 hours), prolonged contact (24 hours to 30 days) and permanent contact (over 30 days), and a needle that is inserted and withdrawn during a procedure generally falls under limited contact. Even within limited contact, however, blood contact adds haemocompatibility, and a design that dwells in tissue for longer moves up a category, bringing in subchronic toxicity, genotoxicity and other endpoints. That is why the correct sequence is to document and fix "what our device contacts, and for how long" before commissioning any testing. Whether the manufacturer's existing overseas test reports can be used is covered separately in the guide to acceptance of foreign test reports.

3. Sterilization validation — a report, not a summary. EO sterilization requires validation to ISO 11135 and radiation sterilization to ISO 11137, and reviewers normally look for evidence that SAL 10⁻⁶ is achieved. The most common misstep in practice is trying to substitute "a sterilization certificate" for the package. What the review expects is a validation report covering everything from equipment qualification through repeat confirmation runs, and for EO sterilization, residual testing data for EO and ECH (ISO 10993-7) comes as part of the set. ISO 10993-7 applies different residual limits according to the device's contact category — conceptually, short-duration devices are controlled against the initial exposure, while long-term and permanent devices are held to a lower average daily exposure. Even a short-contact device such as a biopsy or puncture needle has to demonstrate through a residual test report that it sits within those limits, and the actual residual level depends heavily on whether the aeration conditions immediately after sterilization were adequate. If the aeration process is not included in the validation, a good test result can still get stuck on questions about reproducibility.

4. Sterile packaging and shelf life — proving the shelf life of sterility. Sterility must hold not until shipment but until the point of use. Shelf life is established with ISO 11607-series packaging validation data (seal strength, microbial barrier properties and so on) together with aging studies. "The manufacturer says five years, so five years" is not evidence — the aging period covered by your supporting data is the ceiling on the shelf life you can claim.

Shelf-life evidence is normally generated by running accelerated aging and real-time aging in parallel. Accelerated aging rests on the Q10 concept, a simplification of Arrhenius reaction-rate theory. With Q10 = 2 typically applied, raising the storage temperature by 10°C is taken to roughly double the rate of aging, so samples are held at an elevated temperature in the 40–60°C range for the period corresponding to the target shelf life, after which package integrity (seal strength, gas tightness and the like) is verified. The widely used approach in practice is to set the initial shelf life on the accelerated aging results and go to market, while holding real-time aging samples under the same conditions and using those results, once the actual time has elapsed, to verify and confirm the accelerated value. In short, accelerated aging is the evidence that gets you registered first; real-time aging is the evidence that confirms the claim.

5. Performance testing — short, but the conditions matter. Penetration force (puncture resistance), needle stiffness and corrosion resistance, hub joint strength, and dimensions by gauge are the usual items. For biopsy needles, sampling performance (core yield and similar) may be added. What matters at review is less the list of items than whether the test conditions match your own product specification and whether representativeness across gauges and lengths has been secured. Testing every model in the line-up is rarely feasible, so you generally need a rationale for selecting a worst-case representative model. Worst case differs by test item: for stiffness and penetration force it is the finest gauge and the longest length; for joint strength it is the structurally weakest combination. If the rationale for the representative model is not documented, "why did you test only this model?" becomes a deficiency on its own. How to build the product specification is continued in technical documentation in practice.

Labelling — small, but a frequent cause of rejection

Sterile single-use devices carry unusually detailed labelling requirements. The container and outer packaging must carry the sterilization method, the "single use" and "do not reuse" statements, and the expiry date, and the items required on the unit pack and on the shipping pack must each be correct. For imported products, the consistency between the original-language label and the Korean labelling is also checked. Drafting the label artwork before the technical documentation is finalised reduces rework at the customs stage (see import and customs procedures).

Common causes of rejection and deficiency letters

• Sterilization validation substituted with a certificate or a summary — no IQ/OQ/PQ report submitted
• EO sterilization with missing residual testing data (ISO 10993-7), or an unvalidated aeration process
• Raw material information that stops at "SUS304" — no upstream supply chain certificates
• Contact category used for biological safety testing inconsistent with the actual duration of use
• Mismatch between the shelf-life rationale (the aging study period) and the expiry date on the label
• Insufficient justification of representativeness for the tested model across the gauge and length line-up
• Missing labelling items such as "single use," "do not reuse," or the sterilization statement

Checklist before you start

• Product name and class fixed (single-use sterile or not; design confirmed — core type, aspiration type, etc.)
• Raw materials listed by component + route confirmed for obtaining upstream supply chain material certificates
• Body contact sites and duration categories documented → ISO 10993 test battery derived
• Sterilization method confirmed → ISO 11135/11137 validation report obtained, at least down to the table of contents
• Packaging validation and accelerated/real-time aging data checked for consistency with the shelf life you intend to claim
• Gauge and length line-up organised → rationale prepared for the worst-case representative test model
• Draft label artwork prepared (sterilization, single use, expiry date)

---

Even for a single needle, how ready the sterilization, material and packaging documentation is varies enormously from one manufacturer to the next. Send us the specifications of the models you intend to handle and a list of the documents your manufacturer holds, and our free pre-review will tell you what is already in place and what still has to be built.